These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 17499504)

  • 1. Synthesis and RET protein kinase inhibitory activity of 3-arylureidobenzylidene-indolin-2-ones.
    Rizzi E; Cassinelli G; Dallavalle S; Lanzi C; Cincinelli R; Nannei R; Cuccuru G; Zunino F
    Bioorg Med Chem Lett; 2007 Jul; 17(14):3962-8. PubMed ID: 17499504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, modeling, and RET protein kinase inhibitory activity of 3- and 4-substituted beta-carbolin-1-ones.
    Cincinelli R; Cassinelli G; Dallavalle S; Lanzi C; Merlini L; Botta M; Tuccinardi T; Martinelli A; Penco S; Zunino F
    J Med Chem; 2008 Dec; 51(24):7777-87. PubMed ID: 19053769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of RET tyrosine kinase by SU5416.
    Mologni L; Sala E; Cazzaniga S; Rostagno R; Kuoni T; Puttini M; Bain J; Cleris L; Redaelli S; Riva B; Formelli F; Scapozza L; Gambacorti-Passerini C
    J Mol Endocrinol; 2006 Oct; 37(2):199-212. PubMed ID: 17032739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1.
    Petrangolini G; Cuccuru G; Lanzi C; Tortoreto M; Belluco S; Pratesi G; Cassinelli G; Zunino F
    Biochem Pharmacol; 2006 Aug; 72(4):405-14. PubMed ID: 16756963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.
    Kim DW; Jo YS; Jung HS; Chung HK; Song JH; Park KC; Park SH; Hwang JH; Rha SY; Kweon GR; Lee SJ; Jo KW; Shong M
    J Clin Endocrinol Metab; 2006 Oct; 91(10):4070-6. PubMed ID: 16849418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure and activity relationship of 2-(substituted benzoyl)-hydroxyindoles as novel CaMKII inhibitors.
    Komiya M; Asano S; Koike N; Koga E; Igarashi J; Nakatani S; Isobe Y
    Bioorg Med Chem Lett; 2011 Mar; 21(5):1456-8. PubMed ID: 21292482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and anti-tyrosine kinase activity of 3-(substituted-benzylidene)-1, 3-dihydro-indolin derivatives: investigation of their role against p60c-Src receptor tyrosine kinase with the application of receptor docking studies.
    Olgen S; Akaho E; Nebioglu D
    Farmaco; 2005; 60(6-7):497-506. PubMed ID: 15927182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and pp60c-Src tyrosine kinase inhibitory activities of novel indole-3-imine and amine derivatives substituted at N1 and C5.
    Kiliç Z; Isgör YG; Olgen S
    Arch Pharm (Weinheim); 2009 Jun; 342(6):333-43. PubMed ID: 19475593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl)nicotinonitrile scaffold.
    Brandt W; Mologni L; Preu L; Lemcke T; Gambacorti-Passerini C; Kunick C
    Eur J Med Chem; 2010 Jul; 45(7):2919-27. PubMed ID: 20409618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interplay between Ret and Fap-1 regulates CD95-mediated apoptosis in medullary thyroid cancer cells.
    Nicolini V; Cassinelli G; Cuccuru G; Bongarzone I; Petrangolini G; Tortoreto M; Mondellini P; Casalini P; Favini E; Zaffaroni N; Zunino F; Lanzi C
    Biochem Pharmacol; 2011 Oct; 82(7):778-88. PubMed ID: 21741956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BAY 43-9006 inhibition of oncogenic RET mutants.
    Carlomagno F; Anaganti S; Guida T; Salvatore G; Troncone G; Wilhelm SM; Santoro M
    J Natl Cancer Inst; 2006 Mar; 98(5):326-34. PubMed ID: 16507829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of diversely substituted indolin-2-ones.
    Bouchikhi F; Rossignol E; Sancelme M; Aboab B; Anizon F; Fabbro D; Prudhomme M; Moreau P
    Eur J Med Chem; 2008 Nov; 43(11):2316-22. PubMed ID: 18313174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel aminomethylindole derivatives as inhibitors of pp60c-Src tyrosine kinase: synthesis and biological activity.
    Işgör YG; Kiliç Z; Olgen S
    Chem Biol Drug Des; 2008 Dec; 72(6):599-604. PubMed ID: 19090928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural modification of an EGFR inhibitor that showed weak off-target activity against RET leading to the discovery of a potent RET inhibitor.
    Sun QZ; Xu Y; Liu JJ; Zhang CH; Wang ZR; Zheng RL; Wang WJ; Li LL; Yang SY
    Mol Divers; 2014 May; 18(2):403-9. PubMed ID: 24515340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A redox-linked novel pathway for arsenic-mediated RET tyrosine kinase activation.
    Kato M; Takeda K; Hossain K; Thang ND; Kaneko Y; Kumasaka M; Yamanoshita O; Uemura N; Takahashi M; Ohgami N; Kawamoto Y
    J Cell Biochem; 2010 May; 110(2):399-407. PubMed ID: 20235151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and evaluation of novel 7-azaindazolyl-indolyl-maleimide derivatives as antitumor agents and protein kinase C inhibitors.
    Ye Q; Cao J; Zhou X; Lv D; He Q; Yang B; Hu Y
    Bioorg Med Chem; 2009 Jul; 17(13):4763-72. PubMed ID: 19447039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models.
    Okamoto K; Kodama K; Takase K; Sugi NH; Yamamoto Y; Iwata M; Tsuruoka A
    Cancer Lett; 2013 Oct; 340(1):97-103. PubMed ID: 23856031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and synthesis of N'-(2-oxoindolin-3-ylidene)hydrazide derivatives against c-Met kinase.
    Liang Z; Zhang D; Ai J; Chen L; Wang H; Kong X; Zheng M; Liu H; Luo C; Geng M; Jiang H; Chen K
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3749-54. PubMed ID: 21561768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors.
    Mologni L; Rostagno R; Brussolo S; Knowles PP; Kjaer S; Murray-Rust J; Rosso E; Zambon A; Scapozza L; McDonald NQ; Lucchini V; Gambacorti-Passerini C
    Bioorg Med Chem; 2010 Feb; 18(4):1482-96. PubMed ID: 20117004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.
    Showalter HD; Sercel AD; Leja BM; Wolfangel CD; Ambroso LA; Elliott WL; Fry DW; Kraker AJ; Howard CT; Lu GH; Moore CW; Nelson JM; Roberts BJ; Vincent PW; Denny WA; Thompson AM
    J Med Chem; 1997 Feb; 40(4):413-26. PubMed ID: 9046331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.